Chemoprevention of mammary carcinogenesis in female rats by rofecoxib

Cancer Letters

Volumn 202, Issue 2, 2003, Pages 131-136

  Kubatka, Peter ^a   Ahlers, Ivan ^a   Ahlersová, Eva ^a   Adámeková, Eva ^a   Luk, Pauline ^b   Bojková, Bianka ^a   Marková, Martina ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Chemoprevention; Cyclooxygenase 2; Mammary carcinogenesis; Rat; Rofecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; METHYLNITROSOUREA; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET; DOSE RESPONSE; DRUG EFFECT; FEMALE; FIBROADENOMA; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

EID: 0345303976     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.08.006     Document Type: Article

References (28)

1. Abou_Issa H.M., Alshafie G.A., Seibert K., Koki A.T., Masferrer J.L., Harris R.E. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res. 21:2001;3425-3432.
2. Alshafie G.A., Abou_Issa H.M., Seibert K., Harris R.E. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol. Rep. 7:2000;1377-1381.
3. Anderson W.A., Umar A., Viner J.L., Hawk E.T. The role of cyclooxygenase inhibitors in cancer prevention. Curr. Pharm. Des. 8:2002;1035-1062.
4. Battu S., Rigaud M., Beneytout J.L. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A. Anticancer Res. 18:1998;3579-3583.
5. Brueggemeier R.W., Quinn A.L., Parrett M.L., Joarder F.S., Harris R.E., Robertson F.M. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 140:1999;27-35.
6. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30:2000;3-21.
7. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., Kelloff G.J., Hill D.L., Seibert K. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:2000;5599-5602.
8. Harris R.E., Alshafie G.A., Abou_Issa H., Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60:2000;2101-2103.
9. Harris R.E., Beebe_Donk J., Namboodiri K.K. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol. Rep. 8:2001;655-657.
10. Harris R.E., Beebe_Donk J., Schuller H.M. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol. Rep. 9:2002;693-695.
11. Harris R.E., Kasbari S., Farrar W.B. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol. Rep. 6:1999;71-73.
12. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5:1999;1418-1423.
13. Kawamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
14. Kelloff G.J., Sigman C.C., Greenwald P. Cancer chemoprevention: progress and promise. Eur. J. Cancer. 35:1999;1755-1762.
15. Kubatka P., Kalická K., Chamilová M., Ahlersová E., Ahlers I., Bojková B., Adámeková E. Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats. Neoplasma. 49:2002;255-259.
16. Moore B.C., Simmons D.L. COX-2 inhibition, apoptosis, and chemoprevention by non-steroidal antiinflammatory drugs. Curr. Med. Chem. 7:2000;1131-1134.
17. Môciková-Kalická K., Bojková B., Adámeková E., Mníchová-Chamilová M., Kubatka P., Ahlersová E., Ahlers I. Preventive effect of indomethacin and melatonin on 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in female Sprague-Dawley rats. A preliminary report. Folia Biol. (Praha). 47:2001;75-79.
18. Nakatsugi S., Ohta T., Kawamori T., Mutoh M., Tanigawa T., Watanabe K., Sugie S., Sugimura T., Wakabayashi K. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn. J. Cancer Res. 91:2000;886-892.
19. Nelson J.E., Harris R.E. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol. Rep. 7:2000;169-170.
20. Noguchi M., Tanyia T., Koyasaki N., Kumaki T., Miyazaki I., Mizukami Y. Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptors contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. Cancer Res. 51:1991;2683-2689.
21. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61:2001;1733-1740.
22. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., Falgueyret J.P., Friesen R.W., Gordon R., Greig G., Guay J., Mancini J., Ouellet M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I.W., Gresser M., Ford_Hutchinson A.W., Young R.N., Chan C.C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296:2001;558-566.
23. Rita M., Young I. Eicosanoids and the immunology of cancer. Cancer Met. Rev. 13:1994;337-348.
24. Russo J., Russo I.H., Rogers A.E., van Zwieten M.J., Gusterson B. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the rat. Tumours of the mammary gland. IARC Sci. Publ. 99:1990;47-78.
25. Suzui N., Sugie S., Rahman K.M.W., Ohnishi M., Yoshimi N., Wakabayashi K., Mori H. Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenylimidazo[4,5/b]pyzridine-induced mammary carcinogenesis in rats. Jpn. J. Cancer Res. 88:1997;705-711.
26. Thun M.J., Namboodiri M.M., Heath C.W.J. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325:1991;1593-1596.
27. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA. 94:1997;3336-3340.
28. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.